Insider buying
~$174K19K sh @ $9.40
Traded Apr 9, 2025 · filed 3 days later
A major shareholder of Keros Therapeutics paid $174K out of pocket for Keros Therapeutics shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 9, 2025 · Filed Apr 12, 2025
A major shareholder of Keros Therapeutics paid $768K out of pocket for Keros Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$767,860
Shares × reported transaction price
$500K–$1M
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
42 days after results of Feb 26, 2025, 27 days before results of May 6, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +12.2% | −4.7% | +16.9% |
| 30 days | +6.7% | +9.0% | −2.3% |
| 90 days | +14.4% | +15.9% | −1.5% |
| 180 days | +24.7% | +23.0% | +1.7% |
| 365 days | −9.3% | +28.8% | −38.1% |
Past results only. Not a forecast.
Insider buying
Traded Apr 9, 2025 · filed 3 days later
A major shareholder of Keros Therapeutics paid $174K out of pocket for Keros Therapeutics shares.
Insider buying
Traded Apr 9, 2025 · filed 3 days later
A major shareholder of Keros Therapeutics paid $154K out of pocket for Keros Therapeutics shares.
Insider buying
Traded Apr 9, 2025 · filed 3 days later
A major shareholder of Keros Therapeutics paid $3.2M out of pocket for Keros Therapeutics shares.
ADAR1 Capital Management, LLC, 10% owner's past purchases, 90 days after disclosure: 9 buys, median +2.3 pts vs S&P 500, beat it 6 of 9 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.